These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 33938697)

  • 21. Appearance of lentigines in psoriasis patients treated with apremilast.
    Sfecci A; Khemis A; Lacour JP; Montaudié H; Passeron T
    J Am Acad Dermatol; 2016 Dec; 75(6):1251-1252. PubMed ID: 27846946
    [No Abstract]   [Full Text] [Related]  

  • 22. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
    Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
    Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
    [No Abstract]   [Full Text] [Related]  

  • 24. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
    Pavia G; Gargiulo L; Cortese A; Valenti M; Sanna F; Borroni RG; Costanzo A; Narcisi A
    Dermatol Ther; 2022 Feb; 35(2):e15253. PubMed ID: 34877758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
    Pacifico A; d'Arino A; Pigatto PDM; Malagoli P; Young Dermatologists Italian Network ; Damiani G
    Clin Exp Dermatol; 2021 Oct; 46(7):1344-1346. PubMed ID: 33969530
    [No Abstract]   [Full Text] [Related]  

  • 31. Three cases of palmoplantar pustulosis successfully treated with apremilast.
    Eto A; Nakao M; Furue M
    J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
    [No Abstract]   [Full Text] [Related]  

  • 32. Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis.
    Ivanic MG; Thatiparthi A; Walia S; Liao W; Wu JJ
    J Drugs Dermatol; 2021 Aug; 20(8):837-843. PubMed ID: 34397197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gastrointestinal side effects of apremilast : Characterization and management].
    Pinter A; Beigel F; Körber A; Homey B; Beissert S; Gerdes S; Staubach-Renz P; Radtke MA; Mössner R
    Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R; Levin E; Koo J
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apremilast Decreased Proinflammatory Cytokines and Subsequently Increased Inhibitory ones in Psoriasis: A Prospective Cohort Study.
    Fukasawa T; Yoshizaki-Ogawa A; Enomoto A; Sato S; Yoshizaki A
    Acta Derm Venereol; 2024 May; 104():adv37555. PubMed ID: 38738774
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.
    Ikumi K; Torii K; Sagawa Y; Kanayama Y; Nakada A; Nishihara H; Morita A
    J Dermatol; 2022 Apr; 49(4):e125-e126. PubMed ID: 34961971
    [No Abstract]   [Full Text] [Related]  

  • 39. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous hyperpigmentation induced by apremilast.
    Di Cesare A; Pescitelli L; Ricceri F; Lazzeri L; Prignano F
    Int J Dermatol; 2018 Apr; 57(4):473-474. PubMed ID: 29350406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.